Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪 C-MER EYE CARE HOLDINGS LIMITED 希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 3309)

## VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY DR. DENNIS LAM

This announcement is made by C-MER Eye Care Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis in relation to the increase in the shareholding in the Company held by Dr. LAM Shun Chiu Dennis ("**Dr. Lam**"), the Company's Chairman, chief executive officer and executive Director.

The board (the "**Board**") of directors (the "**Directors**") of the Company was informed by Dr. Lam that, in addition to his purchase of 300,000 shares of the Company (the "**Shares**") on 26 September 2022 (as announced in the announcement dated 26 September 2022), from 27 September 2022 to 30 September 2022, he has further purchased a total of 1,150,000 Shares on market for an aggregate consideration of HK\$4,005,840, representing an average price of approximately HK\$3.48 per Share (the "**27/9 – 30/9 Purchase**") and approximately 0.093% of the issued share capital of the Company, with details as follows.

Date	Total number of Shares	Aggregate consideration	Average price per Shares	Percentage of the issued share capital of the Company
27 September 2022	100,000	HK\$375,720	HK\$3.76	0.008%
27 September 2022 28 September 2022	270,000	HK\$968,940	HK\$3.59	0.008 %
29 September 2022	380,000	HK\$1,282,060	HK\$3.37	0.031%
30 September 2022	400,000	HK\$1,379,120	HK\$3.45	0.032%

Immediately before the 27/9 - 30/9 Purchase, Dr. Lam together with C-MER Group Limited (the controlling shareholder of the Company that is owned as to 70% by Dr. Lam and 30% by Ms LI Xiaoting, his spouse and an executive Director of the Company) hold approximately 55.17% of the issued share capital of Company. After the 27/9 - 30/9 Purchase, Dr. Lam together with C-MER Group Limited now hold approximately 55.27% of the Company.

Dr. Lam has informed the Company that he is confident about the future prospects of the Group and its business, and his decision for making the Purchase also took into account the recent prices of the Shares.

Based on information available to the Company and to the best knowledge of the Board, the Company's public float continues to comply with the requirements under The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited after the Purchase.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution if they deal or contemplate dealing in the securities of the Company.

By order of the Board **C-MER Eye Care Holdings Limited Dr. LAM Shun Chiu Dennis** JP Chairman, Chief Executive Officer and Executive Director

Hong Kong, 30 September 2022

As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis JP, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan, and six independent non-executive Directors, namely, Dr. Rex AUYEUNG Pakkuen GBS JP, Dr. LI Kwok Tung Donald SBS OStJ JP, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong, Ms. BENTLEY Annie Liang, and Mr. IP Shu Kwan Stephen GBS JP.